Summary: Hypertriglyceridemia and hyperlipidemia are the most remarkable metabolic complications seen with long-term sirolimus therapy. We report the case of a 36-year-old woman status post bilateral lung transplantation on a maintenance immunosuppression regimen of sirolimus, tacrolimus, and prednisone who presented with status migrainosus, chest pain, abdominal discomfort, and triglyceride levels greater than 4425 mg/dL. In previously reported cases of severe hypertriglyceridemia that developed on maintenance sirolimus therapy, plasmapheresis has been utilized as an early strategy to rapidly lower triglycerides in order to minimize the risk of acute complications such as pancreatitis, but our case was managed medically without plasmapheresis. The most recent triglyceride was down to 520 mg/dL 2 months after discontinuation of sirolimus. We estimate the probability of this reaction to sirolimus as probable based on a score of 5 points on the Naranjo scale. This is the first case report to our knowledge that highlights the sole use of oral lipid-lowering drug agents to treat severe hypertriglyceridemia secondary to sirolimus without the use of plasmapheresis. Conclusion: Sirolimus-induced severe hypertriglyceridemia can be managed with oral lipid-lowering agents without plasmapheresis. Clinician needs to be aware of the importance of baseline and regular triglyceride monitoring in patients on sirolimus.
Introduction
Sirolimus, also known as rapamune and rapamycin, is a macrocyclic lactone that serves as a potent immunosuppressive agent via binding to FK-binding protein 12 and the mammalian target of rapamycin in order to block interleukin 2-dependent proliferation and stimulation of T-lymphocytes caused by cross-linkage of CD28. 1 There are notable similarities and differences between sirolimus and calcineurin inhibitors in terms of adverse effect profiles. Compared to calcineurin inhibitors, sirolimus has no neurotoxicity or diabetogenic potential and, most importantly, no nephrotoxicity. Sirolimus is associated with unique side effects that include dose-dependent thrombocytopenia, leukopenia, and delayed wound healing, but the most notable metabolic adverse reactions associated with sirolimus are hyperlipidemia (20%-46%) and hypertriglyceridemia (45%-57%). 2, 3 Several studies have shown a steady increase in cholesterol and triglyceride levels in transplant recipients on long-term maintenance sirolimus therapy. 2, 3 Long-term use of sirolimus can result in cases of severe hypertriglyceridemia, defined as triglycerides greater than 1000 mg/dL, where rapid lowering of triglyceride levels must be achieved to prevent the onset of hypertriglyceridemiainduced acute pancreatitis. There is some literature that suggests that early plasmapheresis is the preferred treatment modality for rapid reduction of triglyceride levels. Pharmacologic approaches to hypertriglyceridemia are usually not the first-line choice due to their slower onset of action. 4 However, plasmapheresis is not Food and Drug Administration (FDA) approved for severe hypertriglyceridemia and is rarely used for the indication. The purpose of this case report is to highlight the case of a lung transplant recipient who developed severe hypertriglyceridemia on maintenance sirolimus therapy that was effectively managed with lipid-lowering drug agents without the use of plasmapheresis.
Case Report
A 36-year-old woman with a past medical history was significant for bilateral lung transplantation 2 years ago in 2013 due to pulmonary hypertension who presented with status migrainosus, chest discomfort, abdominal discomfort, and decreased appetite for the last few weeks. She was started on sumatriptan 50 mg as needed for headache and valproic acid intravenous therapy for status migrainosus on admission. Her maintenance immunosuppressive therapy regimen included tacrolimus 3 mg in the morning and 2.5 mg in the evening, sirolimus 2 mg and 1 mg alternating every other day, and prednisone 5 mg daily. Tacrolimus goal range was 4 to 6 mg/L and sirolimus goal range was 4 to 8 mg/L. Tacrolimus and sirolimus ranges of troughs ran 3.7 to 8.0 mg/L and 2.2 to 2.8 mg/L over the last 12 months, respectively. The patient's blood sample on admission was remarkably lipemic, and triglycerides were found to be greater than 4425 mg/dL. Her other laboratory values includes total cholesterol 900 mg/dL, high-density lipoprotein 26 mg/dL, low-density lipoprotein unmeasurable (unable to calculate due to triglyceride level greater than 500 mg/dL), aspartate aminotransferase 35 IU/mL, amino alanine transferase 16 IU/mL, total bilirubin less than 0.2 mg/dL, and international normalized ratio of 2.2. Amylase and lipase were within normal range. The tacrolimus trough level the day after admission was 5.7 mg/dL, and sirolimus level was 2.2 mg/dL.
Her other significant medications prior to this admission included warfarin 5 mg and 7.5 mg alternating every other day for lower extremity deep vein thrombosis in December 2014; valganciclovir 450 mg twice daily; bupropion extended release 300 mg once daily; sulfamethoxazole-trimethoprim 800 mg to 160 mg on Monday, Wednesday, and Friday; and topiramate 25 mg twice daily.
Due to the lack of robust data and non-FDA approved indication for the use of plasmapheresis for severe hypertriglyceridemia, plasmapheresis was not performed and she was started on fenofibrate 145 mg daily and fish oil 2 g every 12 hours. After sirolimus discontinuation, triglyceride level was decreased down to 2673 mg/dL at day 5 and further dropped to 1722 mg/dL at day 10. The headache and chest discomfort were also recovered at day 10. The trends in other lipid parameters are shown in Table 1 .
Due to the discontinuation of sirolimus, the patient was placed back on mycophenolate mofetil 500 mg twice daily (held 2 years ago in 2013 due to intolerant diarrhea), and the previous dosing of tacrolimus and prednisone was continued. All migraine-related symptoms presented on admission were resolved after the patient was placed on valproic acid enteric coated tablet 500 mg every 8 hours.
In the follow-up clinic visit, the triglyceride level decreased to 989 mg/dL at 16 days following admission. Due to persistent abnormal triglyceride levels 1 month later, atorvastatin 20 mg daily and niacin-extended release 500 mg daily were started. The most recent triglyceride dropped down to 520 mg/dL 2 months after discontinuation of sirolimus.
Discussion
To our knowledge, there is only 1 sirolimus-induced severe hypertriglyceridemia transplant patient case with triglyceride levels >1000 mg/dL reported in the literature. 5 FemandezBussy et al reported the first case of sirolimus-induced severe hypertriglyceridemia in the right lung transplantation managed by plasmapheresis, niacin, and a statin. 5 The patient in the case report developed nonspecific symptoms of light headedness and chest discomfort, and triglyceride level was remarkably high 9340 mg/dL on admission. Amylase and lipase were within normal range, 2 sessions of plasmapheresis decreased the triglyceride level down to 594 mg/dL, and all symptoms resolved. Plasmapheresis was not performed in our case due to the lack of robust data and non-FDA approved indication. To our knowledge, our case report was the first case where severe hypertriglyceridemia was successfully managed with medications without plasmapheresis. Multiple lipid-lowering agents for hypertriglyceridemia have been utilized in the literature, but there is limited data reported specifically for sirolimus-induced hypertriglyceridemia. 6, 7 The observational study by Celik et al included 15 adult heart transplant patients who developed hypertriglyceridemia (>150 mg/dL). 6 The mean duration of sirolimus or everolimus treatment was 1.4 years. Triglyceride levels increased from 188 to 354 mg/dL on average. After the administration of fish oil 4 g daily for 4 months, the mean triglyceride levels were significantly improved down to 226 mg/dL. All patients had at least a 20% reduction in triglyceride levels. Brattstrom et al reported the effects of adding pravastatin to a sirolimus dose reduction. This approach resulted in a reduction in triglyceride levels from 1327 to 752 mg/dL after 3 months of therapy. 7 It is controversial whether sirolimus-induced hypertriglyceridemia is dose or trough dependent. The sirolimus level upon admission in the first case by Femandez-Bussy et al was 11 mg/dL and was 2.2 mg/dL in our case. 5 Firpi et al reported 6 cases of sirolimus-induced hypertriglyceridemia in liver transplant recipients also receiving tacrolimus or cyclosporine.
2 It showed that all of patients had therapeutic sirolimus mean trough levels <15 mg/dL but developed significant hypertriglyceridemia. Sirolimus levels in our case had ranged from 2.2 to 2.8 mg/dL. In contrast, other studies show a dose or trough dependence of sirolimus-induced hypertriglyceridemia. 8, 9 Spinelli et al reported that triglyceride concentration was independently associated with sirolimus level (r 2 ¼ .03, P ¼ .005) regardless of cyclosporine level. 9 They concluded that sirolimus-induced hypertriglyceridemia was dependent on sirolimus level.
Based on the Naranjo Adverse Drug Reaction Probability Scale, sirolimus-induced hypertriglyceridemia is probable with 5 points. 10 The sirolimus level was subtherapeutic on admission in our case, and tacrolimus and steroids were additional possible causes. Sirolimus was never rechallenged for our patient as she was restarted on mycophenolate mofetil that does not carry the hypertriglyceridemia side effect profile of sirolimus.
Conclusion
This case demonstrated sirolimus-induced hypertriglyceridemia in a bilateral lung transplant recipient causing nonspecific symptoms managed by discontinuation of sirolimus and lipidlowering agents without emergent therapy with plasmapheresis.
Our case reenforces the importance of baseline and regular triglyceride monitoring in patients on sirolimus, regardless of sirolimus trough levels.
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